



EXPEDITED PROCEDURE - EXAMINING GROUP 1646

S/N 09/150,813

PATENT

TECH CENTER 1600/2900

JAN 4 2001

RECEIVED

NOT ENTERED

#25/D
MB
01/15/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	David J. Grainger et al.	Examiner:	Joseph F. Murphy, Ph.D.
Serial No.:	09/150,813	Group Art Unit:	1646
Filed:	September 11, 1998	Docket:	1543.002US1
Title:	COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE		

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.116

Box AF
Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the final Office Action mailed August 10, 2001, please amend the application as follows:

In the Claims

Please substitute the claim set in the appendix entitled "Clean Version of Pending Claims" for the previously pending claim set. Specific amendments to individual claims are detailed in the following marked-up set of claims.

Please cancel claims 21, 24-28, 31-33, 35, 40, 45, and 48-50 without prejudice.

Please amend the claims as follows.

17. (Twice amended) A method of preventing or inhibiting an indication associated with a chemokine-induced activity, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of a peptide of a chemokine, a variant thereof, a derivative thereof, or a combination thereof, wherein the peptide comprises no more than 30 amino acid residues, [wherein at least three contiguous residues of the peptide correspond to residues in the carboxyl-terminal half of the mature form of the chemokine, wherein the three contiguous residues correspond to residues Trp-Val-Gln or Lys-Gln-Lys in human MCP-1,] wherein the peptide comprises residues X₁-Asp-Pro-X₂-X₃-X₄-Trp-X₅-Gln or consists of X₂-X₃-X₄ or Trp-X₅-Gln, wherein X₁ is Ala or Leu, X₂ is Lys, Ser or Thr, X₄ is Lys, Glu, Ser or Arg, X₅ is Val or Ile, and X₃ is any amino acid, and wherein the peptide inhibits the response induced by [the